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HIV-2 infection is characterized by low viremia and slow disease progression as
compared to HIV-1 infection. Circulating CD14++CD16+ monocytes were found
to accumulate and CD11c+ conventional dendritic cells (cDC) to be depleted in
a Portuguese cohort of people living with HIV-2 (PLWHIV-2), compared to blood
bank healthy donors (HD). We studied more precisely classical monocytes; CD16+
inflammatory (intermediate, non-classical and slan+ monocytes, known to accumulate
during viremic HIV-1 infection); cDC1, important for cross-presentation, and cDC2,
both depleted during HIV-1 infection. We analyzed by flow cytometry these PBMC
subsets from Paris area residents: 29 asymptomatic, untreated PLWHIV-2 from
the IMMUNOVIR-2 study, part of the ANRS-CO5 HIV-2 cohort: 19 long-term
non-progressors (LTNP; infection ≥8 years, undetectable viral load, stable CD4
counts≥500/µL; 17 of West-African origin -WA), and 10 non-LTNP (P; progressive
infection; 9WA); and 30 age-and sex-matched controls: 16 blood bank HDwith unknown
geographical origin, and 10 HD of WA origin (GeoHD). We measured plasma bacterial
translocation markers by ELISA. Non-classical monocyte counts were higher in GeoHD
than in HD (54 vs. 32 cells/µL, p= 0.0002). Slan+ monocyte counts were twice as high in
GeoHD than in HD (WA: 28 vs. 13 cells/µL, p= 0.0002). Thus cell counts were compared
only between participants of WA origin. They were similar in LTNP, P and GeoHD,
indicating that there were no HIV-2 related differences. cDC counts did not show major
differences between the groups. Interestingly, inflammatory monocyte counts correlated
with plasma sCD14 and LBP only in PLWHIV-2, especially LTNP, and not in GeoHD.
In conclusion, in LTNP PLWHIV-2, inflammatory monocyte counts correlated with LBP
or sCD14 plasma levels, indicating a potential innate immune response to subclinical
bacterial translocation. As GeoHD had higher inflammatory monocyte counts than HD,
our data also show that specific controls are important to refine innate immunity studies.
Keywords: HIV-2, monocytes, slan+ monocytes, dendritic cells, cDC1, cDC2, controls
Iannetta et al. Myeloid Cells During HIV-2 Infection
INTRODUCTION
HIV-2 infection (1) is mostly prevalent in West Africa, and in
populations emigrated from West Africa to Portugal and France
(1–3). Eighty-seven per cent of the participants included in the
French ANRS CO5 cohort originate from this geographical area.
Compared to HIV-1 infection, HIV-2 infection is characterized
by undetectable-to-low viremia, slower CD4+ T-cell decline and
activation, slower disease progression (4, 5). The proportion of
long-term non progressors (LTNP) is higher during HIV-2 than
during HIV-1 infection (4). However people living with HIV-2
(PLWHIV-2) develop viral reservoirs with similar levels of HIV
DNA in their PBMCs as people living with HIV-1 (PLWHIV-1)
(6), and untreated HIV-2 infection can lead to AIDS, as current
treatment options are scarcer than for HIV-1 infection (5).
Monocytes and conventional dendritic cells (DC) derive
from common hematopoietic precursors. They are phagocytic,
antigen-presenting cells and they secrete cytokines with effector,
polarizing, inflammatory and reparatory functions. Monocytes
represent 10–20% of peripheral blood mononuclear cells
(PBMC). They are identified by their morphology and the
expression of CD14. Among circulating monocytes, classical
monocytes with a CD14bright, CD16− phenotype represent
the major population (90% of monocytes). Other monocytes,
which will be called “inflammatory monocytes” along this
text, express the FcγIII-receptor CD16, a receptor induced by
microbial or inflammatory stimuli, conferring inflammatory,
scavenger and cytotoxic functions. They comprise intermediate
monocytes (CD14brightCD16+) and non-classical monocytes
(CD14+, CD16+) (7). Circulating non-classical monocyte
(CD14+CD16+) counts are higher in both asymptomatic
chronically HIV-1-infected people with high viremia and in
people developing AIDS than in people with low viremia or in
uninfected donors (8, 9). They were found to be more permissive
to HIV-1 infection in vivo and in vitro than other monocytes
and to correlate with plasma sCD14 levels and microbial
translocation (10, 11). Their accumulation is mostly due to a
subpopulation of slan+ monocytes, inflammatory monocytes
bearing the 6-Sulfo LacNAc (slan) glycosylation variant of the
P selectin glycoprotein ligand 1 (PSGL-1) (12–14). Although
these cells were originally described as a DC subpopulation,
transcriptomic approaches have shown that they coclustered with
monocytes and not with CD1c+ DCs (15, 16). Circulating slan+
monocytes produce higher TNF-α amounts than other monocyte
subpopulations, and higher TNF-α amounts in HIV-1 viremic
than in non-viremic people (13). Slan+ monocytes accumulate
in viremic people (13) as well as in cART virosuppressed people
who have experienced low CD4 count nadirs (14), but they are
depleted during AIDS (17). They are known to be present in
the lesions of major inflammatory chronic diseases like Crohn’s
Abbreviations: cDC, conventional dendritic cells (type 1, cDC1; type 2, cDC2);
EFS, Etablissement Français du Sang (French Blood Bank); GeoHD, healthy donors
matched for geographical origin with PLWHIV-2 from the LTNP and P groups;
HD, healthy donors (the abbreviation in the text is for healthy donors from
the blood bank (EFS); LBP, Lipopolysaccharide-binding protein; LTNP, long-
term non-progressors; P, progressors; PLWHIV, people living with HIV; WA,
West-African.
disease, psoriasis or rheumatoid arthritis, which respond to
therapeutic TNF-α blockade (18, 19). During HIV-2 infection,
CD16+ monocyte numbers were shown to increase significantly
among CD14bright monocytes (20), but slan+ monocytes had
never been specifically studied.
Myeloid or conventional DC (cDC), originally characterized
as CD11c++CD14− cells, negative for other lineage markers,
are depleted from the circulation during HIV-1 infection
(21). They were found to be progressively depleted from the
circulation during chronic HIV-2 infection (20). They were
further delineated into two major populations: cDC1 express
the chemokine receptor XCR1, thrombospondin (CD141), and
receptors for dead cells like Clec9, and are the equivalent of the
murine CD8-α+ DC population, specialized in antigen cross-
presentation to CD8+ T cells; cDC2 express the non-classical
HLA Class I molecule CD1c as well as SIRP-α, and are believed to
stimulate mostly CD4+ T lymphocytes (13, 22–25). Circulating
cDC1 and cDC2 are both depleted during HIV-1 infection (13)
and had not been specifically studied during HIV-2 infection.
During HIV-1 infection, the intestinal epithelium is
durably damaged, allowing microbial product translocation
into the circulation and the lymphoid system (26). This
translocation has been associated with progression to non-
AIDS-related complications like diabetes or cardiovascular
diseases (26, 27). Plasma markers of bacterial translocation
include lipopolysaccharides (LPS), major components of enteric
Gram-negative bacterial outer membrane, which are classically
measured in the plasma using the limulus assay but with low
sensitivity and high variability. CD14, the main co-receptor for
LPS detection, is shed from the surface of classical monocytes
as a soluble molecule into the plasma. Microbial translocation
and correlation with soluble CD14 (sCD14) levels were found
in PLWHIV-1 from the USA, Canada or Finland (11, 26–28). In
the SMART study on chronically HIV-1 infected participants,
plasma sCD14 levels represented the only biomarker correlated
with all-cause mortality, with a relative risk of 6 times in those
with the highest quartile of CD14 levels, compared to those with
the lowest quartile, after adjustment for CD4 cell counts, HIV-1
RNA levels and other inflammatory markers (29). CD163, a
receptor involved in the clearance of hemoglobin, is also cleaved
from monocytes or macrophages upon inflammation, leading
to increased soluble CD163 (sCD163) plasma concentration. In
vitro, it is expressed on M2-type monocytes stimulated with LPS
and IL-4 or IL-13 (30). In PLWHIV-1, sCD163 plasma levels
were found to be higher than in controls, to correlate positively
with viral loads as well as with CD14+CD16+ monocyte counts,
and inversely with the expression of CD163 on these cells and
with CD4+ T cell counts. Also, sCD163 represents a marker of
neurocognitive impairment or atheromatous plaque formation
in people living with HIV (17, 31–33). LPS-binding protein
(LBP), an acute-phase reactant secreted by epithelial intestinal
or hepatic cells in response to inflammation, mediates binding
of the Lipid A part of LPS to CD14. Circulating LBP levels
correlate positively with plasma sCD14 levels during chronic
HIV-1 infection (26, 27).
A recently uncovered particularity during HIV-2 infection
is the lack of intestinal mucosa disruption, and the conserved
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balance between Th17 cells and regulatory T cells (34).
Paradoxically, high levels of plasma sCD14 were found in
the Portuguese HIV-2-infected cohort, as well as a significant
activation of monocytes and DC, with high levels of HLA-DR
and CD86 expression (20), like during HIV-1 infection (35), but
LBP levels were similar to those of controls. In the ANRS CO5
HIV-2 cohort (n = 71), no elevation in plasma sCD14 was noted
compared to healthy donors, but sCD14 levels correlated with IL-
6 and high sensitivity C-reactive protein levels, and inversely with
CD4+ T cell counts. Moreover, participants with plasma sCD14
levels >1.74µg/mL had a 3.59 higher risk of disease progression
than the others (p = 0.004), after adjustment for CD4 counts
(36), like HIV-1 infected participants of the SMART study (29).
sCD163 plasma levels were shown to decrease after cART in
HIV-1-, and less in HIV-2-infected people from the Bissau HIV
cohort (37, 38), but these data were not compared to those from
healthy controls.
Here, we studied cDC1, cDC2 and monocyte subpopulations
including slan+ monocytes, in HIV-2 infected participants from
the IMMUNOVIR-2 study part of the ANRS-CO5 HIV-2 cohort,
in correlation with viral loads and gut translocation markers.
We distinguished long-term non-progressors (LTNP) and non-
LTNPs (P, including progressive and intermediate evolutive
profiles). Moreover, as PLWHIV-2 from the cohort were living
in the Paris area, but originated mostly from West-Africa, we
compared them not only to local Blood Bank healthy donors
(HD), as usually done in many studies performed on HIV-2
infection, but also to local HD matched for their geographical
origin, i.e., originating from West-Africa (GeoHD), in order to
control the influence of ethnicity on our data.
RESULTS
Participant Characteristics
All the participants were residents in the Paris area. Twenty-
nine participants to the French ANRS-CO5 HIV-2 cohort,
adult, asymptomatic and naïve of antiretroviral treatment were
included into two groups depending on progression of HIV-
2 infection: 19 Long-Term Non-Progressors (LTNP), including
17 from West-Africa, or 10 Non-LTNP (i.e., with progressive
infection) (P), including 9 from West-Africa (Table 1). Long
Term non progression was defined by asymptomatic infection
for at least 8 years, with at least three CD4 cell counts or
plasma viral load (pVL) measures during the 5 past years,
stable CD4 cell counts (CD4) ≥ 500/mm3 since at least 5 years
without a rapid decrease in the CD4 cell count slope (i.e., >50
cells/year) during the last 3 years). Thirty healthy donors, age-
and sex- matched with the HIV-2+ participants, 16 from the
French blood bank [Etablissement Français du Sang (EFS)] (HD),
and 10 additionally matched with most HIV2+ participants for
their West-African origin (GeoHD), were enrolled as control
groups. Demographic and biological characteristics of HIV-2+
participants andHD are presented inTable 1. TheHIV-2 P group
was on average older (53 years) than the GeoHD group (42 years),
a statistical difference not significant when considering onlyWest
African participants (Table 1). The sex-ratio varied from 0.78
to 1.83 between the groups. As expected, median CD4+ T cell
counts were lower in HIV-2 P than in LTNP (in West African
participants: 586 vs. 895 cells/µL p= 0.029).
Numbers and Percentages of Monocytes
During HIV-2 Progressive vs.
Non-progressive Infection Compared to
Matched Controls From the Blood Bank or
From West-African Origin
Monocytes were classified according to their CD14 and CD16
expression (Supplementary Figure 1, CD14 vs. CD16 plot)
into three subsets: classical monocytes (blue: CD14++CD16−),
intermediate monocytes (gray: CD14+CD16+) and non-classical
monocytes (yellow: CD14+CD16±), the latter expressing slan
(yellow) or not (dark green). First, we compared monocyte
TABLE 1 | Demographic and clinical characteristics of the HIV-2-infected and uninfected donors participating in this study.
HD GeoHD HIV-2 LTNP HIV-2 P p Dunn or Mann-Whitney p
N 16 19 10 NA NA
West Africans NA 10 17 9
Age, years (median, [IQR]) 50 [41–55] 50 [40–54] 53 [45–59] 0.018 (K-W) GeoHD vs. P, p = 0.015
42 [29–48] 50 [40–54] 53 [44–61] 0.069 (K-W) GeoHD vs. P, p = 0.06
Sex (F/M), (ratio) 7/9 (0.78) 11/8 (1.38) 5/5 (1.00) 0.835 (Chi2)
6/4 (1.50) 11/6 (1.83) 5/4 (1.25) 0.669 (Chi2)
Geographic origin NA 2 France 1 France 0.316 (Chi2)
10 West
Africa
17 West Africa 9 West Africa
CD4, cell/µl (median [IQR]) NA NA 895 [820–1203] 502 [423–858] P vs. LTNP, p = 0.018
895 [823–1187] 586 [356–936] P vs. LTNP, p = 0.029
Viral load, copies/ml
(median [IQR])
NA NA <40 [<40–40], n = 17 <40 [<40–117], n = 9
HD, healthy donors from French blood bank (EFS); GeoHD, healthy donors of West-African origin; HIV-2 LTNP, long-term non-progressor HIV-2-infected donors; HIV-2 P, non-LTNP
HIV-2 infected donors. Italics, West-African origin. NA, not available. IQR, interquartile range. K-W, Kruskall-Wallis. Chi2, Chi square test. Bold, p < 0.05.
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subset relative and absolute counts in GeoHD (West-African
origin) and HD (blood bank). The percentages and absolute
counts of classical monocytes and intermediate monocytes were
similar between GeoHD and HD (Table 2 and Figures 1A–D).
Surprisingly, the percentages and absolute counts of non-classical
monocytes were significantly higher in GeoHD than in HD (2.4
vs. 1.4%, Mann-Whitney test p= 0.004 and 54.1 vs. 31.8 cells/µL,
p = 0.0002, respectively; Table 2 and Figures 1E,F). Slan+
monocyte percentages and absolute counts were significantly
higher in GeoHD compared to HD (1.4 vs. 0.77%, p = 0.005
and 27.9/µL vs. 13.1/µL, p = 0.0002, respectively; Table 2
and Figures 1G,H). Thereafter, cell counts were compared only
between participants of West-African origin: we compared
GeoHD with HIV-2 LTNP (n = 17) and P (n = 9) of West-
African origin (Table 2 and Figure 2). Classical and intermediate
monocyte percentages and counts were similar between these
groups (medians for classical monocytes: 14.0 in GeoHD, 12.1 in
HIV-2 LTNP and 8.8 cells/µL in HIV-2 P), as well as the non-
classical monocyte (54.1 in GeoHD, 61.5 in HIV-2 LTNP and
49.8 cells/µL in HIV-2 P) and the slan-monocyte counts (27.9
in GeoHD, 36.6 in HIV-2 LTNP and 32.8 cells/µL in HIV-2 P).
This was surprising because when compared toHD from the local
blood bank, as in (20), non-classical monocyte counts were twice
as high in HIV-2 LTNP from all origins (n = 19; 61.5 vs. 31.8
cells/µL, Dunn’s post test p = 0.01), and slan+ monocytes too
(36.5 vs. 13.1, p = 0.004). In HIV-2 LTNP from West-African
origin (n = 17), non-classical and slan+ cell counts were also
significantly higher than in HD. No correlation of non-classical
or slan+ monocyte counts was found with either VL or proviral
loads (Supplementary Figure 2). Thus, non-classical monocytes
and among them, slan+ monocyte counts were higher in GeoHD
than in HD, but not between PLWHIV-2 and controls matched
for geographical origin, indicating that the difference was related
to ethnicity rather than to HIV-2 infection.
Numbers and Percentages of Conventional
DC During HIV-2 Progressive vs.
Non-progressive Infection Compared to
Matched Controls From the Blood Bank or
of West-African Origin
Conventional DC were characterized according to the
preferential expression of the surface markers CD141 (BDCA3)
on cDC1 or CD1c (BDCA1) on cDC2, among CD14low, CD16−,
HLA-DR+, CD19− cells (Supplementary Figure 1). Percentages
among total CD45+ PBMC and absolute counts per µL blood
for the two subsets of cDC were compared among the different
groups of HIV-2-infected and uninfected individuals.
cDC1
Conventional DC1 percentages were similar between HD and
GeoHD (Table 2, Figures 3A,B) as well as between PLWHIV-
2 and GeoHD (Table 2, Figures 3E,F). Without one outlier
participant, cDC1 percentages would have been lower in HIV-2
P than in GeoHD (0.034 vs. 0.068% Dunn’s post-test p = 0.029,
Figure 3E), cDC1 absolute counts followed a similar tendency
(0.78 vs. 1.66 cells/µL, Dunn’s p= 0.066, Figure 3F).
cDC2
Conventional cDC2 percentages and counts were similar
between HD and GeoHD and between PLWHIV-2 and GeoHD
(Table 3, Figures 3C,D,G,H).
TABLE 2 | Monocyte subset percentages among CD45+ PBMC and absolute counts in HIV-2- infected and uninfected donors.








%, Median [IQR] 12.4 [10.8–17.1] 12.1 [8.4–14.2] 9.3 [6.9–11.1] 0.044
14.0 [10.3–14.5] 12.06 [8.4–14.2] 8.8 [6.5–10.0] 0.957 0.066
Cell/µl, Median [IQR] 255 [210–339] 335 [211–464] 234 [115–339] 0.230
279 [233–354] 277 [210–394] 209 [114–352] 0.655 0.334
Intermediate
Monocytes
%, Median [IQR] 0.45 [0.34–0.86] 0.60 [0.44–0.86] 0.49 [0.39–0.90] 0.540
1.07 [0.52–1.15] 0.60 [0.42–0.84] 0.51 [0.39–0.96] 0.240 0.299
Cell/µl, Median [IQR] 9.14 [6.66–18.91] 17.7 [11.3–25.7] 11.6 [7.7–30.6] 0.629
20.0 [9.62–27.1] 17.6 [10.5–24.1] 12.2 [8.0–33.4] 0.121 0.905
Non-classical
Monocytes
%, Median [IQR] 1.4[0.9–1.8] 2.86 [1.1–3.3] 2.0 [1.4–3.8] 0.955
2.4 [2.0–3.3] 2.86 [1.1–3.3] 2.0 [1.1–4.3] 0.004 0.937








%, Median [IQR] 0.77 [0.37–1.00] 1.3 [0.7–2.1] 1.3 [0.9–2.1] 0.981
1.4 [1.0–1.8] 1.3 [0.6–2.2] 1.3 [0.7–2.1] 0.005 0.943
Cell/µl, Median [IQR] 13.1 [7.6–20.1] 36.6 [16.9–52.4] 32.8 [18.6–46.3] 0.813
27.9 [22.3–38.8] 36.6 [16.3–54.3] 32.8 [10.7–34.6] 0.0002 0.967
HD, healthy donors from French blood bank (EFS); GeoHD, healthy donors of West-African origin; HIV-2 LTNP, long-term non-progressor HIV-2-infected donors; HIV-2 P, non-LTNP
HIV-2 infected donors. Italics, West-African origin, as in Figure 2. IQR, interquartile range. Bold, p < 0.05.
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FIGURE 1 | Monocyte subset percentages among CD45+ PBMC and absolute counts in controls from the blood bank (HD) compared to controls of West-African
origin (GeoHD). (A) Classical monocyte (CD14++CD16−) percentages among CD45+ PBMC and (B) absolute counts/µL blood, (C) intermediate monocyte
CD14+CD16+ percentages and (D) absolute counts / µL blood, (E) non-classical monocyte (CD14±CD16+) percentages and (F) absolute counts, (G) slan+
monocyte percentages and (H) absolute counts, in the two groups of age- and sex- matched healthy donors residing in the Paris area, one from the French Blood
Bank (EFS) (HD) and the other of West-African origin (GeoHD). Orange: unknown origin, Black: West-African origin. Horizontal bars represent median values.
Mann-Whitney’s post-test p are represented above the horizontal line connecting the compared groups. Kruskall-Wallis tests and descriptive statistics can be found in
Table 2 (in italics for West-African participants).
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FIGURE 2 | Monocyte subset percentages among CD45+ PBMC and absolute counts in HIV-2-infected participants (LTNP and P) and uninfected controls (GeoHD),
all of West African origin. (A) Classical monocyte (CD14++CD16−) percentages among CD45+ PBMC and (B) absolute counts/µL blood, (C) intermediate monocyte
CD14+CD16+ percentages and (D) absolute counts/µL blood, (E) non-classical monocyte (CD14±CD16+) percentages and (F) absolute counts, (G) slan+
monocyte percentages and (H) absolute counts, in GeoHD, HIV-2 LTNP and P groups, all of West-African origin. The data for the GeoHD group are the same as in
Figure 1 Dunn’s post-test p is represented above the horizontal line connecting the compared groups. Horizontal bars represent median values. Kruskall-Wallis tests
and descriptive statistics can be found in Table 2, in italics.
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FIGURE 3 | Conventional cDC1 and cDC2 percentages among CD45+ PBMC and absolute counts. (A) Conventional DC1 percentages among CD45+ PBMC and
(B) absolute counts/µL blood, (C) cDC2 percentages and (D) absolute counts/µL blood, in HD and GeoHD. Orange: unknown origin, Black: West-African origin. (E)
cDC1 percentages and (F) absolute counts, (G) cDC2 percentages and (H) absolute counts, in GeoHD, HIV-2 LTNP and P, all of West-African origin. Horizontal bars
represent median values. Mann-Whitney tests, Kruskall-Wallis tests and descriptive statistics can be found in Table 3 (in italics for West-African participants).
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TABLE 3 | Conventional cDC1 and cDC2 percentages among CD45+ PBMC and absolute counts in HIV-2-infected and uninfected donors.








cDC1 Median [IQR], % 0.050 [0.043–0.091] 0.040 [0.032–0.045] 0.034 [0.025–0.040] 0.060
0.068 [0.043–0.091] 0.040 [0.033–0.049] 0.035 [0.023–0.042] 0.776 0.119
Median [IQR], cell/µl 1.190 [0.700–1.850] 1.020 [0.786–1.470] 0.777 [0.564–1.170] 0.086
1.66 [0.81–2.15] 1.020 [0.820–1.470] 0.782 [0.650–1.19] 0.444 0.213
cDC2 Median [IQR], % 0.487 [0.377–0.653] 0.414 [0.302–0.533] 0.409 [0.236–0.573] 0.425
0.590 [0.482–0.797] 0.414 [0.314–0.507] 0.446 [0.229–0.625] 0.280 0.066
Median [IQR], cell/µl 9.38 [8.21–15.68] 10.90 [7.85–16.98] 9.03 [6.11–20.44] 0.702
13.25 [10.74–16.06] 10.90 [8.05–16.33] 9.19 [5.18–21.02] 0.084 0.336
HD, healthy donors from French blood bank (EFS); GeoHD, healthy donors of West-African origin; HIV-2 LTNP, long-term non-progressor HIV-2-infected donors; HIV-2 P, non-LTNP
HIV-2. Italics, West-African origin, as in Figures 3E–H. IQR, interquartile range.
Effect of Sex on the Numeration of
Monocytes and DC
As men and women have different innate immune responses
(39), and as there were differences in gender ratios between
the different groups of donors, we compared between female
and male individuals the numerations of these populations
where significant differences in myeloid cell counts were noted.
Supplementary Figure 3 shows that there was no difference
according to participant’s sex for classical monocyte percentages
or slan+ monocyte counts, but that the median count of non-
classical monocytes was higher in women than in men (53 vs.
38 cells/µL, Mann Whitney’s p = 0.02), which might bear on
themedians obtained forWest-African LTNPwhose female/male
ratio was the highest.
Correlation Between Bacterial
Translocation and Myeloid Activation
Plasma markers of bacterial translocation and myeloid activation
sCD14, sCD163, and LBP were measured in the plasma from
HIV-2-infected people and GeoHD. As shown in Table 4 and
Figure 4, there was no difference in the levels of these soluble
markers between the groups. In addition, we measured the
plasma concentrations of GM-CSF, an inflammatory cytokine
produced by myeloid and lymphoid cells. GM-CSF plasma levels
can be higher, but moderately, in asymptomatic chronically HIV-
1-infected people than in controls (40), and can be high during
acute HIV-1 infection, predicting a lower viral setpoint (41). In
vitro, GM-CSF induces the differentiation of classical monocytes
into slan+ monocytes (13). In the plasma from all of the HIV-2
infected donors and African individuals studied here, GM-CSF
levels were normal, i.e., below 4 pg/mL, the detection limit of the
test (except GeoHD #17 at 6 pg/mL, who had the second highest
slan+ -monocyte count in this group at 43 cells/µL).
Correlations between plasmatic markers of bacterial
translocation and myeloid cell counts within each group
are shown in Figure 5 for West African participant samples.
A positive correlation was observed between intermediate
monocyte counts and both sCD14 and LBP plasma levels in
TABLE 4 | Comparison of sCD14, sCD163 and LBP plasma levels in HIV-2
infected participants of West-African origin and GeoHD.






























GeoHD, healthy donors; HIV-2 infected donors; HIV-2 LTNP, long-term non-progressor
HIV-2-infected donors; HIV-2 P, non-LTNP HIV-2 infected donors. All donors of West-
African origin, as in Figure 4. Italics, West-African origin. IQR, interquartile range.
all HIV-2-infected donors (LTNP+P) (Spearman correlation
r = 0.45, p = 0.039, and r = 0.53, p = 0.019, respectively,
Figures 5A,B) but not in LTNP donors alone. Similarly, LBP
levels correlated positively with non-classical monocytes (r =
0.62, p= 0.0047) and with slan+ monocytes (r = 0.57, p= 0.011;
Figures 5C,D) in LTNP + P; this correlation was sustained in
LTNP alone (r = 0.71, p = 0.0058 and r = 0.77, p = 0.0019;
Figures 5C,D).
DISCUSSION
Our work establishes, in untreated HIV-2 infected participants
from the IMMUNOVIR-2 study, the blood counts of sub-
populations of monocytes or cDC that were shown previously to
be affected in HIV-1 infected individuals. PLWHIV-2 from this
study lived in the Paris area, and originated mostly from West-
Africa like the majority of PLWHIV-2. Therefore, to control
for the influence of ethnicity on our data, we compared the
counts from PLWHIV-2 of West-African origin not only with
those from age- and sex-matched donors from the Blood Bank
(HD), but also to those from age- and sex-matched healthy
donors of West-African origin (GeoHD). The percentages and
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FIGURE 4 | Plasma concentrations of sCD14, sCD163 and LBP in
HIV-2-infected participants and uninfected controls (GeoHD), all of West
African origin. Plasma concentrations of (A) sCD14, (B) sCD163, and (C) LBP.
Horizontal bars represent median values. Kruskall-Wallis test and descriptive
statistics can be found in Table 4.
counts of circulating inflammatory non-classical monocytes, and
especially slan+ monocytes, were higher in GeoHD than in HD.
Thus, even if the counts of circulating inflammatory non-classical
monocytes, and especially slan+ monocytes, were higher in long-
term non progressor (LTNP) PLWHIV-2 than in HD, they were
not significantly different from those of GeoHD. In the first
FIGURE 5 | Correlations between monocyte counts and plasma
concentrations of sCD14, sCD163, and LBP in HIV-2 infected participants and
uninfected controls (GeoHD), all of West-African origin. Data from PLWHIV-2
(Continued)
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FIGURE 5 | from Figure 2 were correlated to data from Figure 4 by
Spearman’s test. The significant correlations are depicted. (A) Intermediate
monocytes/µL vs. sCD14 plasma concentration. (B–D) Intermediate,
non-classical or slan monocytes/µL vs. LBP. Correlations are given for all
PLWHIV-2 (LTNP + P) or for LTNP alone. Progressor PLWHIV-2 (P) are
indicated in red.
study on myeloid cells performed during HIV-2 infection in
Portugal, high levels of CD14brightCD16+ monocytes had been
found during HIV-2 chronic infection compared to controls
from the local blood bank in Lisbon, Portugal (20). These events
corresponded to the intermediate monocytes and to part of the
non-classical monocytes measured in our work. The female/male
sex ratios were lower in our cohort than in the Portuguese cohort
(1.83 or 1.25, respectively, vs. 2.22), but our global comparison
of non-classical monocyte counts showing higher counts in
females than in males did not contradict the conclusions of both
studies. Thus, in the present study, HIV-2 did not have any
impact on monocyte subpopulations when infected people were
compared to geographically-matched controls. For conventional
DC (cDC1 and cDC2) populations, measured for the first time
in HIV-2-infected people, no statistical difference was found
between GeoHD and HD, neither between PLWHIV-2 and
GeoHD. In the Portuguese cohort, compared to local blood bank
donors, low counts of myeloid DC, defined as (CD16, CD14,
CD3, and CD20)-negative, CD123-negative, HLA-DR+, CD11c+
cells, had been found, and they correlated with viral loads and
with plasma sCD14 levels. The ages of the participants were
comparable (50 or 53 vs. 52 years), and our global cDC1% did not
show any gender-related difference. Compared to the Portuguese
cohort, the IMMUNOVIR-2 cohort had a similar proportion of
participants with undetectable HIV-2 viremia (25/29 vs. 21/25),
but with lower thresholds (40 or 100 vs. 200 copies/mL), lower
maximal VL at sampling (117 vs. 26,263 copies/mL) and higher
CD4 counts [LTNP: 895 CD4T cells/µL, P: 502, number of
participants with CD4 < 350/µL: 2, vs. in the Portuguese cohort
538 cells/µL and 1/3 of the participants with CD4<350/µL (20)].
Thus, the MMUNOVIR-2 cohort had a lower global progression
than the Portuguese cohort, which may explain the absence of
defect in DC population numbers, even though they were defined
more precisely.
As we had found high plasma sCD14 only in HIV-1
infected individuals with high viremia (13), and as HIV-
2-infected participants from the IMMUNOVIR-2 study had
undetectable to low viremia, we were not surprised that they
had normal translocation markers compared to GeoHD. Neither
DC or monocytic population counts nor plasmatic markers
of bacterial translocation were correlated in this study to
viral loads, proviral loads or to progressor status. This is
comparable to the results previously obtained in the larger
ANRS CO5 cohort, where no differences in sCD14 plasma levels
were found between progressors and non-progressors, although
sCD14 levels were predictive of progression (36). Differently
from the HIV-2 infected Portuguese cohort (20), we did not
find any correlations between plasma bacterial translocation
markers and DC counts. However, we found correlations
between inflammatory monocytes expressing surface CD16
(intermediate, non-classical or slan+ monocytes) and plasmatic
markers of bacterial translocation, i.e., LBP or sCD14 levels, like
in former studies in PLWHIV-1 (11). We showed previously
that CD14bright classical monocytes can differentiate in vitro
into slan+ monocytes in the presence of M-CSF and GM-CSF
(13), the latter occasionally found to be detectable in the plasma
during acute or chronic HIV-1 infection (40, 41). However, in
the plasma from all of the HIV-2 infected participants studied
here, GM-CSF levels were undetectable. Similarly, this cytokine
remained undetectable in the plasma of all but one GeoHD.
The distinction between P and LTNP is rarely made in HIV-2-
infected cohorts despite its potential interest. The correlations
between inflammatory monocyte counts and plasma LBP levels
as a sign of microbial translocation found in all HIV-2 infected
donors (LTNP + P) were sustained in LTNP alone, and not
in P alone. This is counter-intuitive, as microbial translocation
and plasmatic inflammation markers are known to increase
with age and with HIV-1 infection independently (28). This
may be due to the low number of progressor participants,
as some of them were in fact non-LTNP, with a relatively
low level of HIV VL compared to other cohorts, as discussed
above. Alternatively, a protective role might be attributed to
inflammatory monocytes (defining here CD16+ monocytes)
against the progression of HIV-2 infection toward AIDS, i.e., in
terms of viral loads or CD4T cell counts. Indeed, these cells have
antibody-dependent cellular phagocytic and cytotoxic effector
functions (42). Therefore it is possible that despite apparent
integrity of the intestinal mucosa (34), microbial translocation
may occur more often in HIV-2 infected individuals than in
healthy donors, inducing stimulation of classical monocytes by
cytokines locally (without systemic dissemination of GM-CSF),
sCD14 shedding, and CD16 and slan surface expression. Thus,
circulating inflammatory monocyte counts may be a sensitive
sign for intestinal mucosa intermittent leakage.
One very interesting lesson from this study is the comparison
of the two control groups. The counts of circulating inflammatory
non-classical monocytes, and especially slan+ monocytes, were
significantly higher in the GeoHD group originating from West-
Africa than in the HD group. The HD control group matched
for sex and age with HIV-2 infected individuals was recruited
at a local blood bank, as usual in many HIV-2 infection
studies. French legal rules require that blood banks do not
collect any data related to ethnicity. However, the origins of
the population in the Paris area are very diverse. Here, for the
IMMUNOVIR-2 participants and after specific approval from
the ethical board, we collected data on birth country, nationality
(original or acquired) and the country where the contamination
occurred. A similar effort was done in the Portuguese cohort
by the classification into “black” or “white” individuals, which
did not give rise to any difference between the two groups
for plasma LPS or for any of the data levels (20). In other
studies, higher percentages of CD14+CD16+ monocytes and
lower percentages of CD14+CD16− monocytes were found
in Africans than in Caucasians, perhaps in relation with
former exposure to pathogens such as Plasmodium falciparum
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and Schistosoma haematobium (43). Higher frequencies of
CD14+CD16+ “proinflammatory” monocytes, with higher
expression of HLA-DR and PD-L1, were also found in a cohort
of 50 healthy volunteer from Entebbe, Uganda than in a cohort of
50 healthy volunteers of similar ages from Lausanne, Switzerland
(44). This difference was not related to gender differences. It
was accompanied by higher CD16+HLA-DR+ “exhausted” NK
cell frequencies, higher effector memory CD4+ and CD8+ T
cell frequencies, and a more activated B cell compartment.
Importantly, proinflammatory monocyte frequencies correlated
negatively with these volunteer’s neutralizing antibody responses
to a live virus vaccine, the licensed yellow fever vaccine 17D
(YF-17D). Other reports on adaptive or innate immunity during
HIV-2 infection were performed in West Africa, with local
controls (4, 45, 46). Comparisons of innate immunity parameters
during HIV-1 infection were also performed between different
countries. For instance, significantly higher plasma sCD14 levels
were found in cART-naive HIV-1-infected donors from Mexico
compared to similar donors from South Africa, along with
other differences in inflammatory biomarkers (47). Untreated,
PLWHIV-1 from Entebbe, Uganda, were found to have low
CD11c+ and CD11c− DC counts like PLWHIV-1 from the UK,
compared to non-African laboratory workers from the UK (48).
These cohorts recruited before the cART era had high viral
loads and low circulating CD4T cell counts. It was claimed
that in Africa, baseline sCD14 plasma levels were lower, and
LBP similar, in 86 HIV-uninfected donors from Uganda (who
seroconverted and were studied longitudinally) compared to
HIV-uninfected donors from the US (median 53 years old, 62.5%
African-Americans, 50% female), and that they did not change
significantly during HIV-1 infection (49). This was contested
by other studies finding microbial translocation during HIV-1
infection in Kenya (50) or in India (51).
Origin differences, whether between countries but also
between socio-economical groups, may have an impact
on innate immunity baseline and pathological parameters
through many factors. (1) Gender induces differences
depending either on gene products or on hormones (39).
(2) Aging clearly has an impact on microbial translocation
and inflammation (28). (3) Coinfections with opportunistic
or other pathogens, hygiene, or microbial and climatic
environment and (4) Medications (antibiotics, anticancer
drugs, immune suppressors, and proton pump inhibitors...)
may also induce microbial translocation. (5) Food and
substance intake, particularly alcohol intake (52) and high
fat diet, are known to have a direct impact on microbial
translocation and on the emergence of inflammation and
metabolic syndrome, as shown experimentally in non-human
primate SIV infection models (53). (6) All these factors may
also affect the development of the immune system during
early life, including fetal life, with differential expansion and
polarization of adaptive and innate immune cell populations,
compartment seeding and epigenetic imprinting. (7) Even
epigenetic imprinting from previous generations may influence
the innate immune response.
Our study has several strengths including (1) the choice of
a cohort of donors from the same geographical origin as most
PLWHIV-2, i.e., West Africa, and its comparison to a state-of-
the-art control cohort from the local Blood Bank, as usually
done in non-West African studies; (2) the identification of long-
term non progressors compared to progressors in the HIV-2
infected cohort; (3) the homogeneity of the HIV-2 cohort, all
asymptomatic, tested before any antiretroviral treatment, and all
without opportunistic infections like tuberculosis, which could
have confounded inflammatory parameters (47); (4) the precise
delineation of monocyte and cDC subpopulations yet unstudied
during HIV-2 infection, (5) the correlation of their frequencies
with plasmatic microbial translocation markers. Inversely, the
limitations are the low numbers of the donors, particularly from
the same sex, due to the changing recommendations of treatment
during the inclusion period (2013–2015, protracted until the end
of 2018), and the legal impossibility to know the origin of the
healthy donors from the Parisian Blood Bank.
In conclusion, this study underlines that the choice of specific
controls, although never perfect, helps refine studies in specific
populations. It shows higher counts of inflammatory monocytes,
and especially slan+ monocytes, in healthy donors of West-
African origin living in the Paris area, than in healthy donors
from the local blood bank. In HIV-2-infected long term non
progressor participants, and not in controls, these inflammatory
monocyte counts correlated with plasmatic markers of microbial
translocation, indicating a potential innate immune response to
subclinical bacterial translocation, and therefore a potentially




Blood samples (Table 1) were collected from participants who
reside in the Paris area. Twenty-nine participants were part of
the ANRS IMMUNOVIR-2 study (part of the French ANRS
HIV-2 CO5 cohort). These participants were adult, asyptomatic,
treatment-naive individuals infected with HIV-2 alone. Nineteen
were non-progressors (LTNP; 11 females, eight males, median
age 50 years, range 21–66 years), with asymptomatic HIV-2
infection ≥8 years, with at least three CD4 cell counts or plasma
viral load (pVL) measures during the 5 past years, stable CD4
cell counts (CD4) ≥ 500/mm3 since at least 5 years without a
rapid decrase in the CD4 cell count slope (i.e., >50 cells/year)
during the last 3 years). Among LTNP, 17 originated from West-
Africa, i.e., either Ivory Coast, Republic of Guinea, Guinea Bissau,
the Gambia, Ghana or Senegal. Ten were non-LTNP (P) (five
females, five males, median age 54 years, range 41–70 years), also
treatment-naive, except for mother-to-child HIV transmission
preventive treatment. Among P, 9 originated from West-Africa.
Exclusion criteria were: Ongoing opportunistic infection or
malignant disease. Moreover, blood samples were collected from
30 age- and sex-matched healthy controls, seronegative for HIV-
1 and HIV-2. Ten of these controls (GeoHD; six females, four
males, median age 42 years, range 29–48 years) originated from
a similar geographic area as most PLWHIV-2, i.e., West-Africa,
based on the collection of the following data: birth country,
nationality, presumed country where contamination occurred.
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Sixteen other controls were also recruited by the blood bank
(EFS-Saint-Antoine-Crozatier) and analyzed as controls, within
an ethical convention with Inserm (seven females, nine males,
median age 46 years). Exclusion criteria for all groups were:
Age <18 years, Hb < 10g/dL in the past blood check less than
a month before inclusion, known evolutive neoplasia, juridic
incapacity. The study was approved by the ethics committee
Comité de Protection des Personnes Ile de France XI. All
subjects gave written informed consent in accordance with the
Declaration of Helsinki. Plasma were collected and kept frozen.
Blood counts were performed by Coulter counting. Peripheral
blood mononuclear cells were isolated by Ficoll density gradient
and labeled immediately.
Flow Cytometry
Peripheral blood mononuclear cells were washed with cold
PBS, stained with LiveDead (Life Technologies, 30 mn on
ice), before adding 5% human serum (Sigma, 15min), washed
with Staining buffer (PBS, EDTA 2mM, BSA 0.5%) and
labeled in Staining buffer (20min on ice), then washed,
fixed in PBS 4% Paraformaldehyde. The following monoclonal
antibodies were used: CD3-QDot605 (clone UCHT1 1/150) from
Invitrogen; M-DC8-FITC (DD-1, 1/20), CD141(BDCA-3)-APC
(AD5-14H12, 1/150) and CD303(BDCA-2)-PE (AC144, 1/10)
from Miltenyi Biotec; CD1c(BDCA-1)-Pacific Blue (L161, 1/400;
Biolegend); CD14-QDot655 (TüK4, 1/100; Invitrogen), CD19-
ECD (J3-119, 1/10; Beckman Coulter), CD11c-AlexaFluor700
(3.9, 1/10; eBioscience); HLA-DR-PerCP (G46-6, 1/10), CD16-
APC-H7 (3G8, 1/40), CD56-PE-Cy7 (NCAM 16.2 1/100), and
CD45-Amcyan (2D1, 1/25) from BD Biosciences. Cells were
washed with permeabilization buffer before flow cytometry
and analysis (LSR II, BD; FlowJo v10.1, TreeStar, USA).
Data acquisition and analysis were performed at the Cochin
Cytometry and Immunobiology Facility. The absolute numbers
of cells per blood microliter were calculated as before (13,
14, 21, 54, 55) by multiplying the Coulter blood count
(performed independently on whole blood collected during
the same blood sampling) of mononuclear cells (monocytes +
lymphocytes), expressed as cells/µL, to the ratio [events for
the population of interest/(lymphocyte + monocyte) events],
expressed as a percentage, from flow cytometric event counts
(Supplementary Figure 1).
Multiplex ELISA
sCD14, sCD163 LBP, and GM-CSF concentrations were
measured in duplicates in the plasma using Human magnetic
Luminex assays (Biotechne, R&D, Lille, France) at the Cochin
Cytometry and Immunobiology Facility.
Statistics
The data from the different groups of donors were analyzed
using the Kruskall-Wallis test with Dunn’s post-tests correction
for multiple testing, and the Mann-Whitney test when there
were only two groups to compare. Chi square test was used to
analyse proportions of female vs. male participants. Correlations
were analyzed by Spearman tests. Differences were defined as
statistically significant when p< 0.05. The Graphpad Prism v6.10
for Mac OS X was used.
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